Skip to main content
Erschienen in: Der Hautarzt 6/2017

17.05.2017 | Basalzellkarzinom | Leitthema

Die Kopfhaut im Alter

Ein dermatoonkologischer Schwerpunktbereich

verfasst von: N. Wroblewski, K. Wylon, C. Ulrich

Erschienen in: Die Dermatologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Nichtmelanozytärer Hautkrebs und seine Frühformen sind aufgrund von steigender Inzidenz und Prävalenz häufige Diagnosen im dermatologischen Alltag. Die Diagnostik erfolgt zumeist klinisch mit konsekutiver histologischer Sicherung. Die Therapie der Wahl bei invasiven Tumoren ist die vollständige Exzision, erst bei nicht möglicher Exzision sollten andere Therapieoptionen wie Bestrahlung und Systemtherapien erwogen werden. Häufig an für ältere Menschen schlecht einsehbaren und erreichbaren Bereichen der Kopfhaut lokalisiert, stellen sie im klinischen Alltag eine besondere Herausforderung für Arzt und Patienten dar. Die Therapieoptionen sind insbesondere im Bereich der Vorstufen zahlreich und sollte individuell auf den Patienten abgestimmt werden. Der größte Risikofaktor für die Entstehung von nichtmelanozytärem Hautkrebs und seinen Frühformen ist die chronische UV-Exposition. Ein möglicher beruflicher Zusammenhang sollte immer erwogen werden. Insbesondere die Prävention durch Patientenedukation und ausreichende Sonnenschutzmaßnahmen steht im Vordergrund. Die Prognose des nichtmelanozytären Hautkrebses verbessert sich signifikant bei frühzeitiger Diagnosestellung und leitliniengerechter Therapie und Nachsorge.
Literatur
1.
Zurück zum Zitat Li WQ, Cho E, Han J, Weinstock MA, Qureshi AA (2016) Male pattern baldness and risk of incident skin cancer in a cohort of men. Int J Cancer 139:2671–2678CrossRefPubMed Li WQ, Cho E, Han J, Weinstock MA, Qureshi AA (2016) Male pattern baldness and risk of incident skin cancer in a cohort of men. Int J Cancer 139:2671–2678CrossRefPubMed
2.
3.
Zurück zum Zitat Farberg AS, Donohue S, Rigel DS (2016) Hat-wearing patterns in spectators attending baseball games: a 10-year retrospective comparison. Cutis 98:181–184PubMed Farberg AS, Donohue S, Rigel DS (2016) Hat-wearing patterns in spectators attending baseball games: a 10-year retrospective comparison. Cutis 98:181–184PubMed
4.
Zurück zum Zitat Glogau RG (2003) Systemic evaluation of the aging face. In: Bolognia JL, Jorizzo JL, Rapini RP (Hrsg) Dermatology. Mosby, Edinburgh, S 2357–2360 Glogau RG (2003) Systemic evaluation of the aging face. In: Bolognia JL, Jorizzo JL, Rapini RP (Hrsg) Dermatology. Mosby, Edinburgh, S 2357–2360
5.
Zurück zum Zitat Grove GL (1989) Physiologic changes in older skin. Clin Geriatr Med 5:115–125PubMed Grove GL (1989) Physiologic changes in older skin. Clin Geriatr Med 5:115–125PubMed
6.
Zurück zum Zitat Waller JM, Maibach HI (2005) Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 11:221–235CrossRefPubMed Waller JM, Maibach HI (2005) Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 11:221–235CrossRefPubMed
7.
Zurück zum Zitat Harvell JD, Maibach HI (1994) Percutaneous absorption and inflammation in aged skin: a review. J Am Acad Dermatol 31:1015–1021CrossRefPubMed Harvell JD, Maibach HI (1994) Percutaneous absorption and inflammation in aged skin: a review. J Am Acad Dermatol 31:1015–1021CrossRefPubMed
8.
Zurück zum Zitat Philips TK (1994) Clinical manifestations of skin aging. In: Squier CH, Hill MW (Hrsg) The effect of aging in oral mucosa and skin. CRC Press, Boca Ranton, S 25–40 Philips TK (1994) Clinical manifestations of skin aging. In: Squier CH, Hill MW (Hrsg) The effect of aging in oral mucosa and skin. CRC Press, Boca Ranton, S 25–40
9.
Zurück zum Zitat Fiers SA (1996) Breaking the cycle: the etiology of incontinence dermatitis and evaluating and using skin care products. Ostomy Wound Manage 42:32–40PubMed Fiers SA (1996) Breaking the cycle: the etiology of incontinence dermatitis and evaluating and using skin care products. Ostomy Wound Manage 42:32–40PubMed
10.
Zurück zum Zitat Suter-Widmer JE (1996) Age and irritation. In: Agner TM, Maibach HI (Hrsg) The irritant contact dermatitis syndrome. CRC Press, Boca Ranton, S 257–265 Suter-Widmer JE (1996) Age and irritation. In: Agner TM, Maibach HI (Hrsg) The irritant contact dermatitis syndrome. CRC Press, Boca Ranton, S 257–265
11.
Zurück zum Zitat Sudel KM, Venzke K, Mielke H et al (2005) Novel aspects of intrinsic and extrinsic aging of human skin: beneficial effects of soy extract. Photochem Photobiol 81:581–587CrossRefPubMed Sudel KM, Venzke K, Mielke H et al (2005) Novel aspects of intrinsic and extrinsic aging of human skin: beneficial effects of soy extract. Photochem Photobiol 81:581–587CrossRefPubMed
12.
Zurück zum Zitat Neerken S, Lucassen GW, Bisschop MA, Lenderink E, Nuijs TA (2004) Characterization of age-related effects in human skin: a comparative study that applies confocal laser scanning microscopy and optical coherence tomography. J Biomed Opt 9:274–281CrossRefPubMed Neerken S, Lucassen GW, Bisschop MA, Lenderink E, Nuijs TA (2004) Characterization of age-related effects in human skin: a comparative study that applies confocal laser scanning microscopy and optical coherence tomography. J Biomed Opt 9:274–281CrossRefPubMed
13.
Zurück zum Zitat Vierkotter A, Schikowski T, Ranft U et al (2010) Airborne particle exposure and extrinsic skin aging. J Invest Dermatol 130:2719–2726CrossRefPubMed Vierkotter A, Schikowski T, Ranft U et al (2010) Airborne particle exposure and extrinsic skin aging. J Invest Dermatol 130:2719–2726CrossRefPubMed
14.
Zurück zum Zitat Kligman AM, Koblenzer C (1997) Demographics and psychological implications for the aging population. Dermatol Clin 15:549–553CrossRefPubMed Kligman AM, Koblenzer C (1997) Demographics and psychological implications for the aging population. Dermatol Clin 15:549–553CrossRefPubMed
15.
Zurück zum Zitat Farage MA, Miller KW, Berardesca E, Maibach HI (2009) Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 10:73–86CrossRefPubMed Farage MA, Miller KW, Berardesca E, Maibach HI (2009) Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 10:73–86CrossRefPubMed
16.
Zurück zum Zitat Farage MA, Miller KW, Elsner P, Maibach HI (2008) Functional and physiological characteristics of the aging skin. Aging Clin Exp Res 20:195–200CrossRefPubMed Farage MA, Miller KW, Elsner P, Maibach HI (2008) Functional and physiological characteristics of the aging skin. Aging Clin Exp Res 20:195–200CrossRefPubMed
17.
Zurück zum Zitat Farage MA, Miller KW, Maibach HI (2010) Degenerative changes in aging skin. Textbook of aging skin. Springer, BerlinCrossRef Farage MA, Miller KW, Maibach HI (2010) Degenerative changes in aging skin. Textbook of aging skin. Springer, BerlinCrossRef
18.
Zurück zum Zitat Farage MA, Miller KW, Elsner P, Maibach HI (2013) Characteristics of the aging skin. Adv Wound Care (New Rochelle) 2:5–10CrossRef Farage MA, Miller KW, Elsner P, Maibach HI (2013) Characteristics of the aging skin. Adv Wound Care (New Rochelle) 2:5–10CrossRef
20.
Zurück zum Zitat Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T (2014) Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol 28:309–313CrossRefPubMed Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T (2014) Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol 28:309–313CrossRefPubMed
21.
Zurück zum Zitat Strunk T, Szeimies RM (2014) Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options. Hautarzt 65:241–254CrossRefPubMed Strunk T, Szeimies RM (2014) Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options. Hautarzt 65:241–254CrossRefPubMed
22.
Zurück zum Zitat Hauschild A, Breuninger H, Kaufmann R et al (2013) Brief S2k guidelines – Basal cell carcinoma of the skin. J Dtsch Dermatol Ges 11(Suppl 3):10–16CrossRefPubMed Hauschild A, Breuninger H, Kaufmann R et al (2013) Brief S2k guidelines – Basal cell carcinoma of the skin. J Dtsch Dermatol Ges 11(Suppl 3):10–16CrossRefPubMed
23.
Zurück zum Zitat Breuninger H, Eigentler T, Bootz F et al (2013) Brief S2k guidelines – Cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11(Suppl 3):37–47CrossRefPubMed Breuninger H, Eigentler T, Bootz F et al (2013) Brief S2k guidelines – Cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11(Suppl 3):37–47CrossRefPubMed
24.
Zurück zum Zitat Hauschild ABH, Kaufmann R, Kortmann RD, Klein M, Werner J, Reifenberger J, Dirschka T, Tischendorf L, Becker JC, Löser C, Vordermark D, Bootz F, Pistner H, Grabbe S, Garbe C (2012) Kurzleitlinie – Basalzellkrazinom der Haut Update Hauschild ABH, Kaufmann R, Kortmann RD, Klein M, Werner J, Reifenberger J, Dirschka T, Tischendorf L, Becker JC, Löser C, Vordermark D, Bootz F, Pistner H, Grabbe S, Garbe C (2012) Kurzleitlinie – Basalzellkrazinom der Haut Update
25.
Zurück zum Zitat Breuninger HET, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Tischdorf L, Becker JC, Löser C, Vordermark D, Pistner H, Garbe C, Grabbe S (2012) Kurzleitinie – Plattenepithelkarzinom der Haut Update Breuninger HET, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Tischdorf L, Becker JC, Löser C, Vordermark D, Pistner H, Garbe C, Grabbe S (2012) Kurzleitinie – Plattenepithelkarzinom der Haut Update
26.
Zurück zum Zitat Bakos RM, Kriz M, Muhlstadt M, Kunte C, Ruzicka T, Berking C (2011) Risk factors for early-onset basal cell carcinoma in a German institution. Eur J Dermatol 21:705–709PubMed Bakos RM, Kriz M, Muhlstadt M, Kunte C, Ruzicka T, Berking C (2011) Risk factors for early-onset basal cell carcinoma in a German institution. Eur J Dermatol 21:705–709PubMed
27.
Zurück zum Zitat Leiter U, Garbe C (2008) Epidemiology of melanoma and nonmelanoma skin cancer – the role of sunlight. Adv Exp Med Biol 624:89–103CrossRefPubMed Leiter U, Garbe C (2008) Epidemiology of melanoma and nonmelanoma skin cancer – the role of sunlight. Adv Exp Med Biol 624:89–103CrossRefPubMed
28.
Zurück zum Zitat Memon AA, Tomenson JA, Bothwell J, Friedmann PS (2000) Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142:1154–1159CrossRefPubMed Memon AA, Tomenson JA, Bothwell J, Friedmann PS (2000) Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142:1154–1159CrossRefPubMed
29.
Zurück zum Zitat Martincorena I, Roshan A, Gerstung M et al (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880–886CrossRefPubMedPubMedCentral Martincorena I, Roshan A, Gerstung M et al (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880–886CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Rettenberg PHG, Horneck G (1999) Instrinsic and extrinsic biomarkers for the assessment of risks from environmental UV radiation. J Epidemiol 9(6 Suppl):78–83CrossRef Rettenberg PHG, Horneck G (1999) Instrinsic and extrinsic biomarkers for the assessment of risks from environmental UV radiation. J Epidemiol 9(6 Suppl):78–83CrossRef
31.
Zurück zum Zitat Buller DB, Cokkinides V, Hall HI et al (2011) Prevalence of sunburn, sun protection, and indoor tanning behaviors among Americans: review from national surveys and case studies of 3 states. J Am Acad Dermatol 65:S114–23CrossRefPubMed Buller DB, Cokkinides V, Hall HI et al (2011) Prevalence of sunburn, sun protection, and indoor tanning behaviors among Americans: review from national surveys and case studies of 3 states. J Am Acad Dermatol 65:S114–23CrossRefPubMed
32.
Zurück zum Zitat Leiter U, Gutzmer R, Alter M et al (2016) Cutaneous squamous cell carcinoma. Hautarzt 67:857–866CrossRefPubMed Leiter U, Gutzmer R, Alter M et al (2016) Cutaneous squamous cell carcinoma. Hautarzt 67:857–866CrossRefPubMed
33.
Zurück zum Zitat Kaufmann RA, Oberholzer PA, Cazzaniga S, Hunger RE (2016) Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. Eur J Dermatol 26:265–270PubMed Kaufmann RA, Oberholzer PA, Cazzaniga S, Hunger RE (2016) Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. Eur J Dermatol 26:265–270PubMed
34.
35.
Zurück zum Zitat Marks R, Foley P, Goodman G, Hage BH, Selwood TS (1986) Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 115:649–655CrossRefPubMed Marks R, Foley P, Goodman G, Hage BH, Selwood TS (1986) Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 115:649–655CrossRefPubMed
36.
Zurück zum Zitat Dodson JM, DeSpain J, Hewett JE, Clark DP (1991) Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 127:1029–1031CrossRefPubMed Dodson JM, DeSpain J, Hewett JE, Clark DP (1991) Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 127:1029–1031CrossRefPubMed
37.
Zurück zum Zitat Fuchs A, Marmur E (2007) The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 33:1099–1101PubMed Fuchs A, Marmur E (2007) The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 33:1099–1101PubMed
38.
Zurück zum Zitat Fernandez-Figueras MT, Carrato C, Saenz X et al (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29:991–997CrossRefPubMed Fernandez-Figueras MT, Carrato C, Saenz X et al (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29:991–997CrossRefPubMed
40.
Zurück zum Zitat Werner RN, Stockfleth E, Connolly SM et al (2015) Evidence- and consensus-based (S3) Guidelines for the treatment of actinic keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. J Eur Acad Dermatol Venereol 29:2069–2079CrossRefPubMed Werner RN, Stockfleth E, Connolly SM et al (2015) Evidence- and consensus-based (S3) Guidelines for the treatment of actinic keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. J Eur Acad Dermatol Venereol 29:2069–2079CrossRefPubMed
41.
Zurück zum Zitat Heppt M, von Braunmuhl T, Berking C (2016) What is new in basal cell carcinoma? Hautarzt 67:876–883CrossRefPubMed Heppt M, von Braunmuhl T, Berking C (2016) What is new in basal cell carcinoma? Hautarzt 67:876–883CrossRefPubMed
42.
Zurück zum Zitat Mills KC, Kwatra SG, Feneran AN et al (2012) Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol 148:1422–1423CrossRefPubMedPubMedCentral Mills KC, Kwatra SG, Feneran AN et al (2012) Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol 148:1422–1423CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Yosipovitch G, Mills KC, Nattkemper LA et al (2014) Association of pain and itch with depth of invasion and inflammatory cell constitution in skin cancer: results of a large clinicopathologic study. JAMA Dermatol 150:1160–1166CrossRefPubMedPubMedCentral Yosipovitch G, Mills KC, Nattkemper LA et al (2014) Association of pain and itch with depth of invasion and inflammatory cell constitution in skin cancer: results of a large clinicopathologic study. JAMA Dermatol 150:1160–1166CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Olsen EA, Abernethy ML, Kulp-Shorten C et al (1991) A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 24:738–743CrossRefPubMed Olsen EA, Abernethy ML, Kulp-Shorten C et al (1991) A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 24:738–743CrossRefPubMed
45.
Zurück zum Zitat Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335–339PubMed Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335–339PubMed
46.
Zurück zum Zitat Andrews MD (2004) Cryosurgery for common skin conditions. Am Fam Physician 69:2365–2372PubMed Andrews MD (2004) Cryosurgery for common skin conditions. Am Fam Physician 69:2365–2372PubMed
47.
48.
Zurück zum Zitat Nashan D, Meiss F, Muller M (2013) Therapeutic strategies for actinic keratoses – a systematic review. Eur J Dermatol 23:14–32PubMed Nashan D, Meiss F, Muller M (2013) Therapeutic strategies for actinic keratoses – a systematic review. Eur J Dermatol 23:14–32PubMed
49.
Zurück zum Zitat Thai KE, Fergin P, Freeman M et al (2004) A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 43:687–692CrossRefPubMed Thai KE, Fergin P, Freeman M et al (2004) A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 43:687–692CrossRefPubMed
50.
Zurück zum Zitat Overmark M, Koskenmies S, Pitkanen S (2016) A retrospective study of treatment of squamous cell carcinoma in situ. Acta Derm Venereol 96:64–67CrossRefPubMed Overmark M, Koskenmies S, Pitkanen S (2016) A retrospective study of treatment of squamous cell carcinoma in situ. Acta Derm Venereol 96:64–67CrossRefPubMed
51.
Zurück zum Zitat de Vries K, Prens EP (2015) Laser treatment and its implications for photodamaged skin and actinic keratosis. Curr Probl Dermatol 46:129–135CrossRefPubMed de Vries K, Prens EP (2015) Laser treatment and its implications for photodamaged skin and actinic keratosis. Curr Probl Dermatol 46:129–135CrossRefPubMed
52.
Zurück zum Zitat Wollina U, Konrad H, Karamfilov T (2001) Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 3:63–66CrossRefPubMed Wollina U, Konrad H, Karamfilov T (2001) Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 3:63–66CrossRefPubMed
53.
Zurück zum Zitat Ostertag JU, Quaedvlieg PJ, Neumann MH, Krekels GA (2006) Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg 32:261–267PubMed Ostertag JU, Quaedvlieg PJ, Neumann MH, Krekels GA (2006) Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg 32:261–267PubMed
54.
Zurück zum Zitat Szeimies RM, Stockfleth E, Popp G et al (2010) Long-term follow-up of photodynamic therapy with a self-adhesive 5‑aminolaevulinic acid patch: 12 months data. Br J Dermatol 162:410–414CrossRefPubMed Szeimies RM, Stockfleth E, Popp G et al (2010) Long-term follow-up of photodynamic therapy with a self-adhesive 5‑aminolaevulinic acid patch: 12 months data. Br J Dermatol 162:410–414CrossRefPubMed
55.
Zurück zum Zitat Stockfleth E, Kerl H, Zwingers T, Willers C (2011) Low-dose 5‑fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108CrossRefPubMed Stockfleth E, Kerl H, Zwingers T, Willers C (2011) Low-dose 5‑fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108CrossRefPubMed
56.
Zurück zum Zitat Hauschild A, Stockfleth E, Popp G et al (2009) Optimization of photodynamic therapy with a novel self-adhesive 5‑aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 160:1066–1074CrossRefPubMed Hauschild A, Stockfleth E, Popp G et al (2009) Optimization of photodynamic therapy with a novel self-adhesive 5‑aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 160:1066–1074CrossRefPubMed
57.
Zurück zum Zitat Vegter S, Tolley K (2014) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLOS ONE 9:e96829CrossRefPubMedPubMedCentral Vegter S, Tolley K (2014) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLOS ONE 9:e96829CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Sotiriou E, Ioannides D, Vrani F et al (2017) Daylight Photodynamic Therapy vs. Conventional Photodynamic Therapy as skin cancer preventive treatment in patients with face and scalp cancerization: an intra-individual comparison study. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.14177 PubMed Sotiriou E, Ioannides D, Vrani F et al (2017) Daylight Photodynamic Therapy vs. Conventional Photodynamic Therapy as skin cancer preventive treatment in patients with face and scalp cancerization: an intra-individual comparison study. J Eur Acad Dermatol Venereol. doi:10.​1111/​jdv.​14177 PubMed
59.
Zurück zum Zitat Iraji F, Siadat AH, Asilian A, Enshaieh S, Shahmoradi Z (2008) The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 7:167–172CrossRefPubMed Iraji F, Siadat AH, Asilian A, Enshaieh S, Shahmoradi Z (2008) The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 7:167–172CrossRefPubMed
60.
Zurück zum Zitat Malvehy J, Roldan-Marin R, Iglesias-Garcia P, Diaz A, Puig S (2015) Monitoring treatment of field cancerisation with 3 % diclofenac sodium 2.5 % hyaluronic acid by reflectance confocal microscopy: a histologic correlation. Acta Derm Venereol 95:45–50CrossRefPubMed Malvehy J, Roldan-Marin R, Iglesias-Garcia P, Diaz A, Puig S (2015) Monitoring treatment of field cancerisation with 3 % diclofenac sodium 2.5 % hyaluronic acid by reflectance confocal microscopy: a histologic correlation. Acta Derm Venereol 95:45–50CrossRefPubMed
61.
Zurück zum Zitat Pflugfelder A, Welter AK, Leiter U et al (2012) Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3 % diclofenac in 2.5 % hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 26:48–53CrossRefPubMed Pflugfelder A, Welter AK, Leiter U et al (2012) Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3 % diclofenac in 2.5 % hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 26:48–53CrossRefPubMed
62.
Zurück zum Zitat Shergill B, Zokaie S, Carr AJ (2013) Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 8:35–41PubMedPubMedCentral Shergill B, Zokaie S, Carr AJ (2013) Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 8:35–41PubMedPubMedCentral
63.
Zurück zum Zitat Loven K, Stein L, Furst K, Levy S (2002) Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990–1000CrossRefPubMed Loven K, Stein L, Furst K, Levy S (2002) Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990–1000CrossRefPubMed
64.
Zurück zum Zitat Pomerantz H, Hogan D, Eilers D et al (2015) Long-term efficacy of topical fluorouracil cream, 5 %, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 151:952–960CrossRefPubMed Pomerantz H, Hogan D, Eilers D et al (2015) Long-term efficacy of topical fluorouracil cream, 5 %, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 151:952–960CrossRefPubMed
65.
Zurück zum Zitat Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E (2007) A randomised study of topical 5 % imiquimod vs. topical 5‑fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‑year follow-up. Br J Dermatol 157(Suppl 2):34–40CrossRefPubMed Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E (2007) A randomised study of topical 5 % imiquimod vs. topical 5‑fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‑year follow-up. Br J Dermatol 157(Suppl 2):34–40CrossRefPubMed
66.
Zurück zum Zitat Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S (2010) Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3‑week cycles. J Am Acad Dermatol 62:573–581CrossRefPubMed Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S (2010) Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3‑week cycles. J Am Acad Dermatol 62:573–581CrossRefPubMed
67.
Zurück zum Zitat Stockfleth E, Sibbring GC, Alarcon I (2016) New topical treatment options for actinic keratosis: a systematic review. Acta Derm Venereol 96:17–22CrossRefPubMed Stockfleth E, Sibbring GC, Alarcon I (2016) New topical treatment options for actinic keratosis: a systematic review. Acta Derm Venereol 96:17–22CrossRefPubMed
68.
Zurück zum Zitat Korman N, Moy R, Ling M et al (2005) Dosing with 5 % imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141:467–473CrossRefPubMed Korman N, Moy R, Ling M et al (2005) Dosing with 5 % imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141:467–473CrossRefPubMed
69.
Zurück zum Zitat Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B (2012) Ingenol mebutate gel for actinic keratosis. N Engl J Med 366:1010–1019CrossRefPubMed Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B (2012) Ingenol mebutate gel for actinic keratosis. N Engl J Med 366:1010–1019CrossRefPubMed
70.
Zurück zum Zitat Garbe C, Basset-Seguin N, Poulin Y et al (2016) Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a randomized, controlled 12-month study. Br J Dermatol 174:505–513CrossRefPubMed Garbe C, Basset-Seguin N, Poulin Y et al (2016) Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a randomized, controlled 12-month study. Br J Dermatol 174:505–513CrossRefPubMed
71.
Zurück zum Zitat Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK (2013) Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 149:666–670CrossRefPubMed Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK (2013) Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 149:666–670CrossRefPubMed
72.
Zurück zum Zitat van Loo E, Mosterd K, Krekels GA et al (2014) Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 50:3011–3020CrossRefPubMed van Loo E, Mosterd K, Krekels GA et al (2014) Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 50:3011–3020CrossRefPubMed
73.
Zurück zum Zitat Mosterd K, Krekels GA, Nieman FH et al (2008) Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5‑years’ follow-up. Lancet Oncol 9:1149–1156CrossRefPubMed Mosterd K, Krekels GA, Nieman FH et al (2008) Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5‑years’ follow-up. Lancet Oncol 9:1149–1156CrossRefPubMed
74.
Zurück zum Zitat Basset-Seguin N, Hauschild A, Grob JJ et al (2015) Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 16:729–736CrossRefPubMed Basset-Seguin N, Hauschild A, Grob JJ et al (2015) Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 16:729–736CrossRefPubMed
75.
Zurück zum Zitat Migden MR, Guminski A, Gutzmer R et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 16:716–728CrossRefPubMed Migden MR, Guminski A, Gutzmer R et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 16:716–728CrossRefPubMed
76.
Zurück zum Zitat Dummer R, Guminski A, Gutzmer R et al (2016) The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75:113–125.e5CrossRefPubMed Dummer R, Guminski A, Gutzmer R et al (2016) The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75:113–125.e5CrossRefPubMed
77.
Zurück zum Zitat Lacouture ME, Dreno B, Ascierto PA et al (2016) Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 21:1218–1229CrossRefPubMedPubMedCentral Lacouture ME, Dreno B, Ascierto PA et al (2016) Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 21:1218–1229CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Maubec E, Petrow P, Scheer-Senyarich I et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426CrossRefPubMed Maubec E, Petrow P, Scheer-Senyarich I et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426CrossRefPubMed
79.
Zurück zum Zitat Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A (2013) The natural history of actinic keratosis: a systematic review. Br J Dermatol 169:502–518CrossRefPubMed Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A (2013) The natural history of actinic keratosis: a systematic review. Br J Dermatol 169:502–518CrossRefPubMed
80.
Zurück zum Zitat Thompson SC, Jolley D, Marks R (1993) Reduction of solar keratoses by regular sunscreen use. N Engl J Med 329:1147–1151CrossRefPubMed Thompson SC, Jolley D, Marks R (1993) Reduction of solar keratoses by regular sunscreen use. N Engl J Med 329:1147–1151CrossRefPubMed
81.
Zurück zum Zitat Ulrich C, Jurgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78–84CrossRefPubMed Ulrich C, Jurgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78–84CrossRefPubMed
82.
Zurück zum Zitat Darlington S, Williams G, Neale R, Frost C, Green A (2003) A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 139:451–455CrossRefPubMed Darlington S, Williams G, Neale R, Frost C, Green A (2003) A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 139:451–455CrossRefPubMed
83.
Zurück zum Zitat Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH (1995) High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 131:170–175CrossRefPubMed Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH (1995) High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 131:170–175CrossRefPubMed
84.
Zurück zum Zitat Krutmann J, Berking C, Berneburg M, Diepgen TL, Dirschka T, Szeimies M (2015) New strategies in the prevention of actinic keratosis: a critical review. Skin Pharmacol Physiol 28:281–289CrossRefPubMed Krutmann J, Berking C, Berneburg M, Diepgen TL, Dirschka T, Szeimies M (2015) New strategies in the prevention of actinic keratosis: a critical review. Skin Pharmacol Physiol 28:281–289CrossRefPubMed
85.
Zurück zum Zitat Lademann J, Schanzer S, Richter H et al (2004) Sunscreen application at the beach. J Cosmet Dermatol 3:62–68CrossRefPubMed Lademann J, Schanzer S, Richter H et al (2004) Sunscreen application at the beach. J Cosmet Dermatol 3:62–68CrossRefPubMed
87.
Zurück zum Zitat Chen AC, Martin AJ, Choy B et al (2015) A phase 3 randomized trial of Nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618–1626CrossRefPubMed Chen AC, Martin AJ, Choy B et al (2015) A phase 3 randomized trial of Nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618–1626CrossRefPubMed
88.
Zurück zum Zitat Leitlinienprogramm Onkologie. Deutsche Krebsgesellschaft DK A (2014) S3-Leitlinie Prävention Von Hautkrebs, Langversion 1.1. AWMF Registernummer: 032/052ol Leitlinienprogramm Onkologie. Deutsche Krebsgesellschaft DK A (2014) S3-Leitlinie Prävention Von Hautkrebs, Langversion 1.1. AWMF Registernummer: 032/052ol
Metadaten
Titel
Die Kopfhaut im Alter
Ein dermatoonkologischer Schwerpunktbereich
verfasst von
N. Wroblewski
K. Wylon
C. Ulrich
Publikationsdatum
17.05.2017
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 6/2017
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-017-3988-2

Weitere Artikel der Ausgabe 6/2017

Der Hautarzt 6/2017 Zur Ausgabe

Einführung zum Thema

Erkrankungen der Kopfhaut

Passend zum Thema

ANZEIGE

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1]. 

ANZEIGE

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1]. 

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH